Short Interest in NuCana plc (NASDAQ:NCNA) Declines By 15.7%

NuCana plc (NASDAQ:NCNA) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 121,700 shares, a decline of 15.7% from the December 31st total of 144,300 shares. Based on an average trading volume of 149,300 shares, the short-interest ratio is currently 0.8 days. Currently, 3.3% of the shares of the company are sold short.

NuCana Stock Performance

NCNA stock traded down $0.05 during mid-day trading on Monday, hitting $0.97. The company had a trading volume of 65,337 shares, compared to its average volume of 96,745. The stock’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $2.43. NuCana has a 12 month low of $0.85 and a 12 month high of $19.41. The firm has a market cap of $2.56 million, a PE ratio of -0.09 and a beta of 0.97.

NuCana (NASDAQ:NCNA) last posted its quarterly earnings results on Monday, November 25th. The company reported ($2.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.49) by $1.21. Equities analysts anticipate that NuCana will post -12.86 earnings per share for the current year.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.